Daridorexant, a double orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA), has been recently introduced in the market for the treatment of insomnia. DORAs are a new form of sleep drugs that can be used instead of standard positive allosteric gamma-amino butyric acid (GABA)-A receptor modulators. Daridorexant blocks the effects of the wake promoting orexin (also known as hypocretin) neuropeptides by binding specifically to both orexin receptors. This approach avoids the extensive inhibition of neuronal circuits that positive allosteric GABA-A receptor modulators cause, as well as the related adverse effects. In this reviewdetailed Pharmacology of Daridorexant including its mechanism of action, Pharmacodynamics, and Pharmacokinetics have been compiled.